We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Counters Pfizer’s CEO on Second Paxlovid Course After Rebound
FDA Counters Pfizer’s CEO on Second Paxlovid Course After Rebound
One day after Pfizer CEO Albert Bourla said physicians could prescribe a second course of the company’s oral COVID-19 treatment Paxlovid to patients who suffer a rebound, the FDA refuted the executive’s statement.